Beyond traditional chemotherapy, cetuximab, an anti-EGFR monoclonal antibody, counteracts the Warburg effect by inhibiting HIF-1α regulated lactate dehydrogenase A (LDH-A), thus, disrupting the metabolic reprogramming that promotes cancer cell survival [44]. Here, HIF1A is linked to cancer.